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Self-reported testing, HIV status and associated
risk behaviours among people who inject drugs
in Europe: important differences
between East and West
Anneli Uusku¨laa, Mait Raaga, Cinta Folchc, Leoni Prasadd,
Anda Karnitee, Maaike G. van Veenf, Ksenia Eritsyang,
Magdalena Rosinskah, Don C. Des Jarlaisb and Lucas Wiessingi
Aims: To describe HIV-related risk behaviours, HIV testing and HIV status among
people who inject drugs (PWIDs) in the 2000 in European countries with high-
prevalence HIV epidemics among PWID.
Methods: Data from 12 cross-sectional studies among PWID from seven countries
were used. Meta-analysis was used to synthesize the data and meta-regression to
explain heterogeneity [in addition to deriving adjusted odds ratios (AORmeta)].
Results: Data on 1791 PWID from western (the West) and 3537 from central and
eastern (the East) European countries were available. The mean age of participating
PWIDs was 30.6 years (SD 7.9), 75% were men, and 36% [95% confidence interval
34–37%)wereHIV-infected (30%West, 38% East); 22%had not previously been tested
for HIV. The prevalence of reported high-risk behaviour was significantly higher among
PWID from the East. Comparison of HIV-infected and uninfected PWID within
countries yielded similar results across all countries: HIV-infected PWID were less
likely to be sexually active [AORmeta 0.69 (0.58–0.81)], reported less unprotected sex
[AORmeta 0.59 (0.40–0.83)], but reportedmore syringe sharing [AORmeta 1.70 (1.30–
2.00)] and more frequent injecting [AORmeta 1.40 (1.20–1.70)] than their HIV-
uninfected counterparts.
Conclusion: Despite the absolute differences in reported risk behaviours among PWID
in western and eastern Europe, the associations of risk behaviours with HIV status were
similar across the sites and regions. There is a substantial potential for further HIV
transmission and acquisition based on the continuous risk behaviours reported. HIV
prevention and harm reduction interventions targeting PWID should be evaluated.
 2014 Wolters Kluwer Health | Lippincott Williams & Wilkins
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Introduction
About 16 million individuals in 148 countries inject
various illicit drugs, and about 3 million of these are
probably infected with HIV [1]. Although people who
inject drugs (PWIDs) constitute only 0.34% of the global
population, they account for approximately 10% of the
global HIV epidemic [2] and almost one-third of HIV
incidence outside sub-Saharan Africa. New HIV
epidemics among PWID are also emerging in Africa
[3,4].
The majority of HIV-infected PWIDs reside in eastern
Europe and south-east Asia [5]. In 2011, close to 54 000
new HIV diagnoses were in the WHO European
Region. Within this region, the highest rates of diagnosed
cases occurred in the East (22.4 per 100 000 population),
followed by the West (6.5) and the Centre (1.6) [6].
Eastern Europe has the fastest growing HIV epidemic in
the world, due mainly to drug injecting [7]. In western
Europe, a long-term decline in injection drug use-related
infections has been observed [8], although since 2010,
new outbreaks have been reported in Greece and
Romania [9].
Two studies described knowledge of HIV serostatus and
preventive behaviour among PWIDs in Europe [10,11] in
the early to mid-1990s. These suggested a positive effect
of knowing one’s HIV serological status on reducing risk
behaviours. However, there were only minor improve-
ments between 1990 and 1992–1993, indicating that
prevention of HIV transmission among PWIDs must be
reinforced. Since then, significant developments in HIV
prevention and care have occurred in western Europe due
to opioid substitution treatment (OST), needle and
syringe programmes (NSPs) and antiretroviral treatment
(ART) [12,13]. Implementing evidence-based HIV-
prevention interventions, particularly involving multiple
interventions, can avert HIV epidemics and reduce
incidence among PWIDs [14,15]. In recent years, ART
has emerged as a promising intervention to reduce
infectiousness and sexual transmission of HIV [16].
Ecologic evidence also suggests that expansion of ART
among HIV-infected drug injectors may reduce trans-
mission [17]. Further, whereas in western Europe, the last
increase in injection drug use occurred during the 1980s
and 1990s, in several eastern European countries, the
rapid expansion of injection drug use and related HIV
epidemics emerged only around the turn of the century
[18].
Our objective was to examine risk behaviour and HIV
status among current PWIDs since 2000, in European
countries with high-prevalence HIV epidemics among
PWIDs. We compared self-reported data from HIV-
infected and uninfected PWIDs in western European
countries (the West, ‘old epidemics’, starting before 2000
and generally with well developed HIV prevention
programmes); and eastern European countries (the East,
‘new epidemics’, starting after 2000, with limited/
developing HIV prevention programmes).
Methods
A centralized dataset containing data from sero-beha-
vioural surveillance and research studies across Europe
was established by the European Monitoring Centre for
Drugs and Drug Addiction (EMCDDA). Further details
on this collaborative project are presented elsewhere
[19,20]. For the current analysis, data from 12 cross-
sectional studies among current PWIDs conducted in
countries with high-prevalence HIV epidemics among
PWIDs were included (Appendix 1, Table 1, http://links.
lww.com/QAD/A520). Only studies conducted since
2001 were included. Methods of the included studies are
described in detail elsewhere [21–27]; therefore, only a
summary is presented here (Appendix 1, http://links.
lww.com/QAD/A520).
Sampling procedures and recruitment of patients
in included studies
During 2001–2010, surveys and HIV testing were
carried out in various venues (mainly via low threshold
programmes/NSPs and drug treatment programmes) in
current PWIDs (defined as those admitting injection drug
use within the past 6 months). Sampling/recruitment
approaches suitable for hard-to-reach populations were
used: respondent-driven sampling (RDS) (n¼ 6), other
chain referral methods (n¼ 2), and venue-based con-
venience sampling (n¼ 4). Information about self-
reported drug use, injection and sexual risk behaviour
was obtained. Recall periods for risk behaviours (syringe
sharing, unprotected sex) varied between sites with a
maximum of 12 months (Appendix 1, Table 2, http://
links.lww.com/QAD/A520). Participants were also asked
about previous HIV testing. Blood or oral fluid specimens
were obtained for HIV testing. Serum specimens were
tested for HIV antibodies using standard enzyme
immunoassays (see Appendix 1 for more details,
http://links.lww.com/QAD/A520).
Statistical analysis
Univariate statistics of frequency, central tendency, and
dispersion were used to describe demographics, sexual
behaviour (those reporting unprotected sex with main,
casual or paying partners were considered as having
unprotected sex, i.e. not always using condoms), drug use
(those reporting injecting daily or more often were
considered to be frequent injectors), and HIV sero-status.
Odds ratios (ORs) and 95% confidence intervals (CIs)
were used for comparisons (between HIV-infected and
not infected). Adjusted ORs (AORs) and 95% CIs were
calculated using a logistic regression model, adjusting
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for drug injecting career length, age (as a continuous
variable), and sex.
We present an analysis of data collected by period at
different sites and different times. We used meta-analytic
techniques [28] as the studies used different research
methods (sampling strategies, units of measurement). We
also examined the heterogeneity using stratified analyses
and meta-regression (I2 is provided as a measure of
heterogeneity). The meta-variables used for heterogen-
eity assessment included region (western vs. eastern
Europe), sampling methodology (RDS and other chain
referral vs. time/location and convenience/venue-based
sampling), study year, and recall period for the risk
behaviour (number of sexual partners, condom use,
injection frequency and syringe sharing recall periods).
R2 was calculated to measure the variance explained
by meta-variables [28]. Random-effects models with
restricted maximum likelihood estimate for between-
studies variance were employed to combine unadjusted
ORs (ORmeta) and adjusted ORs (AORmeta). Com-
bined ORs with 95% CIs are presented. The significance
level was set at 0.05.
The following groupings of data collection sites and
sampling methods were used:
(1) PWID studies conducted in the Netherlands (2002–
2003), Spain (three sites) (2001–2009), and Portugal
(2009–2010) were defined as studies from western
Europe, whereas studies in Poland (2004–2005), Latvia
(2007), Estonia (2007–2009), and Russia (4 sites)
(2007–2009) were defined as studies from eastern
Europe.
(2) Studies recruiting participants using chain referral
methods (RDS, snowball) were compared with studies
using convenience sampling (including venue-based
sampling, e.g. clients in services).
Additionally, we considered country-level variables:
coverage with NSP, methadone maintenance therapy
(MMT), proportion of PWIDs with imprisonment
experience and problem alcohol consumption [proxy,
adult (15þ years) male per capita consumption of pure
alcohol] to see if they could explain the observed
differences between western and eastern Europe.
Sensitivity analysis (by calculating ratios of adjusted ORs
derived from meta-analysis) was used to examine
robustness of the findings [29]. We used ratios of the
meta-analysis ORs to assess the importance of different
inclusion/exclusion criteria and different assumptions.
Ratios close to 1.0 indicate that changing the inclusion/
exclusion criteria or underlying assumptions would not
affect the results.
Statistical software R version 2.15.1 with the metafor
package was used.
Results
Cross-sectional data were obtained from seven countries:
Estonia, Russian Federation (4 sites), Latvia, Netherlands,
Poland, Portugal, and Spain (3 sites), resulting in a total of
12 data sets (sites) (see Appendix 1, http://links.lww.-
com/QAD/A520).
Data were available for 5373 current PWIDs. HIV
serostatus was available for 5328 (1791 from the West,
3537 from the East). The mean age of participants was
30.6 years (SD 7.9) and 75% were men. About a third
(34%) of the PWIDs were new injectors (injecting for
5 years or less) in the East, compared with about a quarter
(23%) in the West (chi-square test P< 0.0001, difference
of proportions 11%, 95% CI 8–13%). Significant
differences in demographic profile and self-reported
(risk) behaviours among PWIDs in western and eastern
Europe were observed (Table 1). PWIDs from western
Europe were less likely to be HIV-infected (West vs. East:
30 vs. 38%; P< 0.0001).
There were significant differences in the prevalence of
reported sexual risk behaviours among PWIDs by HIV
status in western and eastern Europe (Table 2). Any
unprotected sex was reported by 47% of the HIV-infected
in the West and 70% in the East (P< 0.0001, difference of
proportions 23%, 95% CI 18–30%), and among HIV-
uninfected by 58 and 82% respectively (P< 0.0001,
difference of proportions 24%, 95% CI 19–27%). HIV-
infected PWIDs in the East were more likely to report
syringe sharing. Details about syringe sharing permitting
distinctions between distributive sharing (passing on a
syringe one has already used) and receptive sharing (using
a syringe used by someone else) were available from four
sites. Distributive sharing by HIV-infected PWIDs was
reported by 32% in both Estonia and Latvia (East), vs.
23% in Spain and 6% in the Netherlands (West). Rates of
distributive sharing did not differ by serostatus [AOR-
meta 1.04 (0.83–1.30), I2 0%] or testing status (ever or
never) [AORmeta 1.12 (0.70–1.78), I2 58%] in these four
sites. Receptive sharing by HIV-uninfected PWIDs was
reported by 33, 44, 16, and 8% in Estonia, Latvia, Spain,
and the Netherlands, respectively.
In the West, 46% of the HIV-positive PWIDs reported
frequent injecting compared with 64% in the East
(P< 0.01, difference of proportions 18%, 95% CI 13–
24%). Among HIV-negative PWIDs, frequent injecting
was reported by 44% in the West and 49% in the East
(P¼ 0.0026, difference of proportions 5%, 95% CI
1–8%).
Despite differences in self-reported prevalence of risk
behaviours, the comparison of HIV-infected and unin-
fected PWIDs within the countries yielded similar results
(in terms of effect sizes and direction), with notable
overlap in CIs for all ORs. Namely, HIV-infected PWIDs
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were less likely to be sexually active [AORmeta 0.69
(0.58–0.81)] or report unprotected sex than their HIV-
uninfected counterparts [AORmeta 0.58 (0.40–0.83)]
(Table 2). However, HIV-infected PWIDs reported
higher injection-related risks: syringe sharing [AORmeta
1.70 (1.30–2.00)] and injecting frequently [AORmeta
1.40 (1.20–1.70)] (Table 2).
Heterogeneity was high (I2¼ 76%) for the association of
self-reported unprotected sex and HIV seropositivity. In
our analysis, 0% of the variance was explained by the
sampling methodology, 20% by the study year, and 43%
by the condom use recall period.
Acknowledging that availability of harm reduction
interventions in the Russian Federation was lower than
in other countries of this analysis, we performed a
sensitivity analysis omitting the Russian data. Calculated
ratios of AORs (from the meta-analysis: AOR_Russia
excluded/AOR_Russia included) for the comparisons
provided in Table 2 were close to 1 (point estimates of
AOR ratios ranging from 0.93 to 1.16; all 95% CIs
indicating no significant difference from unity; data
available on request).
We also tested the effect of selected country-level
contextual factors (coverage of needle/syringe pro-
grammes, OST, criminalization of PWIDs – measured
as the proportion of PWIDs ever imprisoned, and
problem alcohol consumption measured at the country
level). As per meta-regression model estimates, these
factors did not significantly contribute to the between-
studies variance (explaining from 0 to 7% of estimates
of I2).
Further, the HIV-infected were more likely to have been
tested for HIV before the interview [AORmeta 1.60
(1.30–2.10)]. Overall, 78% of PWIDs had ever been
tested for HIV. Of those, PWIDs who reported having
tested HIV-negative (n¼ 2723, 70%), 15% were HIV-
infected by the time of the interview (8% in the West,
19% in the East).
One-fifth (22%) of current PWIDs reported never
having been tested for HIV (West vs. East: 11 vs. 27%;
P< 0.0001, difference of proportions 17%, 95% CI
15–19%).
Discussion
Our study documents significant differences between
PWIDs in western and eastern Europe, that is between
those who have experienced the older vs. the more recent
HIVepidemics among PWIDs in Europe. In parallel with
significantly higher HIV prevalence among PWIDs in the
East, consistently higher prevalences of risk behaviours
were reported (e.g. East vs. West: syringe sharing 32 vs.
13%), suggesting a potential for further expansion of the
more recent epidemics.
Testing for HIV is a prerequisite for several HIV
prevention interventions and linkage to HIV care
[30–32]. Given that one-fifth of all PWIDs had never
been tested and HIV prevalence is substantial even among
those who had been previously tested, there is a need for
continuous, sustained, population-based HIV testing for
PWIDs in Europe.
Despite the absolute differences in reported risk
behaviours, the associations of risk behaviours with
HIV status (HIV-positive or negative) were similar across
the sites and the two regions. The robustness of cross-site/
region behaviour patterns is further supported by our
finding of only minor changes in measures of association
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Table 1. Socio-demographic risk behaviour characteristics of people who inject drugs and HIV prevalence in western and eastern Europe 2001–
2010 in countries with high-prevalence HIV epidemics among people who inject drugs.
All
(N¼5548)
Western Europe
(n¼2011)
Eastern Europe
(n¼3537)
P-valuea
(West vs. East)
Age (mean, SD) 30.6 (7.9) 34.5 (8.5) 28.6 (6.8) <0.0001
Sex (% of men) 75% 80% 73% <0.0001
Duration of injection drug use (years, mean, SD) 10.4 (7.5) 13.3 (8.7) 8.9 (6.3) <0.0001
New injectors (injecting 5 years; n/%) 1582 (30%) 408 (23%) 1174 (34%) <0.0001
Frequent injectors (injecting daily þ, %) 51% 44% 55% <0.0001
Sharing (yes, %) 26% 13% 32% <0.0001
Sexually inactive (past 12 months) (%) 20% 30% 14% <0.0001
One sexual partner (past 12 months) (% of all sexual
active IDUs)
49% 53% 48% 0.0009
Sex work (yes, %) 14% 11% 16% < 0.0001
Always using condoms (yes, %; main, casual,
commercial partners combined)
29% 44% 22% < 0.0001
Never tested for HIV (before the study, %) 22% 11% 27% < 0.0001
Tested HIV positive before study (% of those ever tested) 30% 27% 32% < 0.0001
HIV prevalence (%, 95% CI) 36% (34–37%) 30% (28–32%) 38% (37–40%) < 0.0001
CI, confidence interval; IDU, injection drug use.
aWilcoxon rank sum test P-value for comparing age and duration of injection drug use; Fisher’s exact tests p-value for comparing proportions.
Copyright © Lippincott Williams & Wilkins. Unauthorized reproduction of this article is prohibited.
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(OR) after multiple regression and meta-regression
analysis. According to our results, HIV-infected PWIDs
in both eastern and western Europe are more likely to
report previous HIV testing, injecting at least daily, and
equipment sharing than their HIV-negative counterparts,
and, significantly, HIV-infected PWIDs were less likely to
be sexually active and reported less unprotected sex.
Previous studies have given conflicting results: reporting
either no difference in risk behaviour among PWIDs by
HIV status (in Myanmar [33], Indonesia [34], USA [35]
and Mexico [36]), increased injection risks in HIV-
positives (in Nigeria [37] and India [38]) or decreased
injection risks in HIV-positives (in Canada [39]).
Comparison of HIV risk behaviours among PWIDs by
HIV status calls for further systematic literature review,
accounting for contextual factors such as HIV testing rates
and awareness of seropositivity in the PWID population,
HIV prevalence, stage of the HIV or injection drug use
epidemic, availability of harm reduction and health (HIV)
services (including ART coverage among PWIDs), the
policy (law enforcement and security) and economic
environment.
On the basis of the observed risk behaviour among
PWIDs, there is still a substantial potential for HIV
transmission in PWIDs. Ongoing HIV acquisition is
shown by the significant numbers of new HIV infections
among those whose self-reported last HIV test before the
interview was negative. Sizeable proportions of HIV-
infected PWIDs also reported unprotected sex and
syringe sharing. In parallel, there is significant potential
for HIV acquisition among HIV-uninfected PWIDs,
given that two-thirds report unprotected sex and a quarter
syringe sharing. Providing user-friendly, integrated
services and truly accessible HIV prevention and care
services to this target group [40] remains a significant
implementation aim and challenge, especially in eastern
Europe.
Our study has several limitations. We used data from
cross-sectional studies in which the temporality between
exposure (risk behaviours or HIV testing) and outcome
(HIV seropositivity or risk behaviours) cannot be
established. However, observing consistently reduced
risk behaviours among the HIV-infected PWIDs across
sites/regions supports the hypothesis that, following
testing, HIV-positive PWIDs engage in less sexual risk
behaviour than the HIV-negative ones. This is probably
due to a reduction in sexual risk behaviour following a
positive test, as the alternative explanation that those who
report less sexual risk behaviour are more likely to get
infected seems unlikely. We also acknowledge that the
data were derived from multiple studies with some
differences in the behavioural measures (especially
regarding recall periods). However, the resulting errors
would probably apply in a similar manner to both groups
(HIV-infected/uninfected) within sites, and would
therefore not affect comparisons between these groups.
Social desirability bias would potentially also lead to
similar effects (i.e. underestimation) on the measures
of association.
We used data from a variety of sites and contexts across
Europe and from studies employing different methods.
We see a strength of the current analysis in the
methodology (meta-analysis/regression) used. Use of
meta-analysis/regression enabled us to take into account
individual studies context and assess methodological
heterogeneity and thus distinguish effects of these factors
(site, measures, timing, recruitment methods) from
underlying behavioural patterns.
Finally, our results might not be generalizable to all
PWIDs in Europe given that the data came from
countries with high HIV prevalence among PWIDs and
because convenience sampling was used in some studies.
However, these countries are among the most affected by
injection drug use and HIVepidemics, and we believe our
findings therefore have significance for the wider
European HIV epidemic among PWIDs.
In conclusion, PWIDs in eastern Europe (where HIV
epidemics are more recent) engage in higher and more
frequent risk behaviours than PWIDs in the West (where
the HIVepidemics are older). Whether this represents the
‘natural course of an epidemic’ or might (also) reflect
differences in the coverage of interventions [12] warrants
further analysis.
Compared with HIV-negative PWIDs, those infected
with HIV are engaging in less sexual transmission
behaviour, but exhibit higher injection-related trans-
mission risks, suggesting different factors affecting these
risk behaviours.
There is still a substantial potential for further HIV
transmission among PWIDs in Europe, given the high
levels of self-reported risk behaviours. Thus, an
intensification of HIV prevention and harm reduction
interventions targeting this population group is war-
ranted, especially in eastern Europe.
Testing for HIV is a prerequisite for effective HIV
prevention and care, and should be expanded.
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